X4 Pharmaceuticals, Inc. has entered into a significant purchase agreement with Lincoln Park Capital Fund, LLC, granting the company the right to sell up to $40 million worth of its common stock to Lincoln Park. The agreement, effective from June 23, 2025, spans a 24-month term during which X4 Pharmaceuticals can control the timing and amount of stock sales. A registration rights agreement was also established to facilitate this process. As part of the arrangement, X4 issued 137,099 shares to Lincoln Park as a commitment fee, though it will not receive cash proceeds from this issuance. The company plans to use any proceeds from the stock sales for working capital and general corporate purposes.